The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden

Catherine Isitt; Daniel Sjöholm; Maria-Pia Hergens; Fredrik Granath; Pontus Nauclér

doi:10.1016/j.vaccine.2022.03.061

The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden

Vaccine. 2022 May 3;40(20):2823-2827. doi: 10.1016/j.vaccine.2022.03.061. Epub 2022 Mar 29.

Authors

Catherine Isitt¹, Daniel Sjöholm², Maria-Pia Hergens³, Fredrik Granath², Pontus Nauclér⁴

Affiliations

¹ Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Sweden. Electronic address: catherine.isitt@regionstockholm.se.
² Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden.
³ Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Sweden; Department of Communicable Disease Control and Prevention, Stockholm County Council, Stockholm, Sweden.
⁴ Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Sweden. Electronic address: pontus.naucler@regionstockholm.se.

Abstract

Vaccination against SARS-CoV-2 started in Region Stockholm, Sweden in December 2020 with those in long-term care facilities or receiving home care vaccinated first followed by those aged over 80 years. In this population-based, retrospective cohort study, we performed a Poisson regression to model the expected incidence of infections and deaths which we compared to the observed incidence and compared this to an unvaccinated control group of those aged 18-79 years. The aim of this study was to measure the early impact of the vaccination programme in Region Stockholm. Infections and deaths reduced substantially amongst the first two groups targeted for SARS-CoV-2 vaccination with an estimated total 3112 infections prevented, and 854 deaths prevented in these two groups from 4 weeks after the introduction of vaccination through to 2nd May 2021.

Keywords: COVID-19; Cohort study; Long-term-care-facilities; SARS-CoV2; Vaccines.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines
COVID-19* / epidemiology
COVID-19* / prevention & control
Humans
Retrospective Studies
SARS-CoV-2*
Sweden / epidemiology
Vaccination

Substances

COVID-19 Vaccines